基本信息
浏览量:1
职业迁徙
个人简介
His research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies. He has published more than 270 research articles on a variety of topics, including the molecular basis of lung cancers and the development of targeted therapies for patients with specific genomic alterations in lung cancer. He is one of the investigators who discovered epidermal growth factor receptor mutations, which have enhanced the treatment of lung cancer throughout the world. He also led the studies that led to the US Food and Drug Administration approval of dabrafenib plus trametinib for BRAF-mutant non–small cell lung cancer.
Dr Johnson served on the ASCO Board of Directors from 2008 to 2011, received the ASCO Cancer Foundation Translational Research Professorship in 2008, and was selected as an ASCO fellow in 2012. He was elected president of ASCO for the 2017-2018 term and served as immediate past president in 2018-2019.
Dr Johnson served on the ASCO Board of Directors from 2008 to 2011, received the ASCO Cancer Foundation Translational Research Professorship in 2008, and was selected as an ASCO fellow in 2012. He was elected president of ASCO for the 2017-2018 term and served as immediate past president in 2018-2019.
研究兴趣
论文共 114 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2023)
William Zhao, Benjamin Kepecs,Navin R. Mahadevan,Åsa Segerstolpe, Jason L. Weirather, N. Besson,Bruno Giotti,Brian Y. Soong,Chendi Li,Sébastien Vigneau,Michal Slyper,Isaac Wakiro,
bioRxiv (Cold Spring Harbor Laboratory) (2023)
引用0浏览0引用
0
0
Nature Communicationsno. 1 (2023): 7496-7496
Cellno. 18 (2021): 4734-4752.e20
Cellno. 25 (2021): 6119-6137.e26
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn